Lotzová E
Department of General Surgery, University of Texas, M. D. Anderson Cancer Center, Houston 77030.
Leuk Lymphoma. 1992 May;7(1-2):15-28. doi: 10.3109/10428199209053598.
Although the application of biological therapy for solid tumors with cytokines and adoptively transferred activated lymphocytes has received substantial attention, this approach has not been actively explored in treatment of hematopoietic neoplasms. This review will address the possibilities of interleukin-2 (IL-2) and IL-2 activated natural killer (NK) cells and T cells in antileukemia reactivity and therapy. The new approaches to optimal activation and generation of oncolytic cells, selective propagation of lymphocyte subsets, and the role of adhesion molecules in antileukemia cytotoxicity will also be addressed. We trust that this article will be conducive to the development of new directions in leukemia research and treatment.
尽管应用细胞因子和过继转移活化淋巴细胞进行实体瘤生物治疗已受到广泛关注，但这种方法在造血系统肿瘤治疗中尚未得到积极探索。本综述将探讨白细胞介素-2（IL-2）以及IL-2活化的自然杀伤（NK）细胞和T细胞在抗白血病反应性及治疗中的可能性。同时还将讨论溶瘤细胞最佳活化和产生的新方法、淋巴细胞亚群的选择性增殖以及黏附分子在抗白血病细胞毒性中的作用。我们相信本文将有助于白血病研究和治疗新方向的发展。
